McMeekin, D Scott <br/><br/>
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.  [electronic resource] 

 -  Gynecologic oncology  Nov 2012 
 - 356-61 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2012.07.095  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--therapeutic use<br/>Angiogenic Proteins--blood<br/>Biomarkers, Tumor--blood<br/>Carcinosarcoma--blood<br/>Drug Administration Schedule<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Humans<br/>Middle Aged<br/>Survival Analysis<br/>Thalidomide--therapeutic use<br/>Treatment Outcome<br/>Uterine Neoplasms--blood